UC Professor Joins National NIH Advisory Council

CINCINNATI—Margery Gass, MD, professor of obstetrics and gynecology at the University of Cincinnati (UC), is one of six new members nationwide appointed to the advisory council of the National Center for Complementary and Alternative Medicine (NCCAM).

 

Gass’s extensive research experience includes menopause, osteoporosis and female sexual function. She is a principal investigator for the Women’s Health Initiative and a past member of the executive committee for the study.

 

Gass also heads the University Hospital Menopause and Osteoporosis Center and is a past president and board member of the North American Menopause Society.

 

The NCCAM advisory council is part of the National Institutes of Health. Its members, who serve a four-year term, include physicians, scientists, licensed complementary and alternative medicine practitioners and representatives of the public.

 

Council members offer advice and recommendations on the prioritization, conduct and support of complementary and alternative medicine research. This includes research training and disseminating health information derived from the NCCAM’s findings.

 

“I am honored to be a member of this advisory council,” says Gass. “NCCAM provides a wonderful opportunity to promote research in the area of alternative medicine. We need to know which therapeutic approaches are effective and how they work.”

 

“I encourage investigators and practitioners in the area of alternative medicine to submit research proposals to NCCAM,” she says.

 

For more information on the NCCAM, visit www.nccam.nih.gov.

Tags

Related Stories

1

ChemoID test leads to better outcomes in platinum-resistant...

April 7, 2025

MSN and MSN UK highlighted results from a new Phase 3 trial published in the journal npj Precision Oncology that found a cancer stem cell test can accurately choose more effective treatments and lead to improved outcomes for patients with platinum-resistant ovarian cancer.

2

Study: Platform-predicted treatments improve outcomes for...

April 4, 2025

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that an assay that includes an assessment of cancer stem cell sensitivity to chemotherapy can accurately decide more effective treatments and lead to increased outcomes for patients with platinum-resistant ovarian cancer.

Debug Query for this